Evoke Pharma Inc., of San Diego, said Phase IIb data published in Neurogastroenterology & Motility showed that intranasal delivery of metoclopramide was more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide.